Pfizer's Quality by Design Approach to Trial Management - Pharmaceutical Executive

ADVERTISEMENT

Pfizer's Quality by Design Approach to Trial Management

Pharmaceutical Executive


The trial master file: a case for change

The TMF is the definitive source of clinical trial documentation that provides evidence that patient rights and safety have been protected and that the integrity of the trial data, study analysis, and study conclusions are credible. While the TMF is the primary source of information needed to reconstruct and demonstrate the conduct and validity of a clinical trial, the underlying process of managing and maintaining the TMF for clinical trials is often broken and fragmented. TMFs today, which consist of both electronic and paper document formats, are generally scattered across a large and complex network of clinical trial systems and document repositories. An average clinical trial easily generates 10,000 documents with larger trials producing more than 100,000 documents. This means that a large global pharmaceutical company's TMF can contain millions of documents. With the vast amount of data stored in multiple locations, locating documents becomes particularly challenging, time consuming, and subject to frequent procedural errors. In addition, TMF users and contributors often span different geographies, locations, and functions, making standardization of the TMF processes even more challenging, particularly as pharmaceutical companies begin to heavily outsource their clinical trial execution activities. Finally, with the rapidly changing regulatory landscape and introduction of new requirements, pharmaceutical companies are struggling to maintain compliance with regulatory expectations and requirements for the TMF.

In recent inspections across a number of pharmaceutical companies, regulatory health authorities, including the MHRA, EMA, and FDA, have placed a higher level of scrutiny on the TMF as supporting evidence that appropriate procedures were being followed during a clinical trial. Pharmaceutical companies and CROs alike have struggled to maintain regulatory compliance and have often been cited for inability to provide a full TMF for inspection. As a result, the industry is making a concerted effort to address these challenges and meet regulatory requirements. One notable example is a multi-year effort led by a Drug Information Association working group that established a common TMF reference model. This group, comprised of participants from more than 150 pharmaceutical companies including Pfizer, as well as regulatory agencies such as the FDA and MHRA, has helped drive standardization across the industry. The discussion and activity around the TMF continue to gain momentum, as evidenced by a number of industry conferences focused specifically on the TMF this year, which has more than tripled compared to two years ago.

Pfizer's response


TMF process redesign effort included four key steps.
Pfizer addressed the challenges it faced with the TMF by overhauling its processes and technology systems. The decision to utilize the QbD approach rather than other standard process improvement methodologies was based on the desire to achieve "zero defects" in its TMF by building quality into the process. In the specific application of QbD to Pfizer's TMF process, the TMF was treated as the "end product," with a focus on designing the process to reduce the number of defects, i.e. missing or incorrect documents. Though the premise of building quality into the TMF process and routinely monitoring it to enable consistent quality may seem simple and even basic, it is a paradigm shift for the industry. For many companies, the TMF has traditionally been a "graveyard" repository of clinical trial documents filed as an afterthought and relatively forgotten until the time of an audit or inspection. In an effort to reduce the overall cost of poor quality, Pfizer has developed a dynamic solution which enables active contribution, organization, maintenance, and monitoring of TMF documents. As part of the solution, Pfizer has built the necessary controls and measures to proactively manage quality in real time.


ADVERTISEMENT

blog comments powered by Disqus

Source: Pharmaceutical Executive,
Click here